Description

Simple

An antibiotic used to treat a wide variety of infections in the body.

Clinical

A fourth generation fluoroquinolone used to treat a wide variety of infections in the body.

Overview

Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan.

Pharmacology

Indication

For the treatment of bronchitis, sinusitis, community-acquired pneumonia, and skin infections (abscesses, wounds) caused by S. pneumoniae, H. influenzae, S. aureus, M. pneumoniae, C. pneumoniae, L. pneumophila, S. pyogenes

Pharmacodynamic

Gatifloxacin is a synthetic broad-spectrum 8-methoxyfluoroquinolone antibacterial agent for oral or intravenous administration. is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting requir... Read more

Mechanism of action

The bactericidal action of Gatifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.

Absorption

Well absorbed from the gastrointestinal tract after oral administration with absolute bioavailability of gatifloxacin is 96%

Protein binding

20%

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

7-14 hours

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

  • Hypersensitivity:
    • quinolones
  • Regions: US

Food Interactions

  • Drink plenty of fluids.
  • Take with or without food. The absorption is unaffected by food.

Interactions

Type in a drug name to check for interaction with Gatifloxacin
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Gatifloxacin.
(S)-Warfarin
The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Gatifloxacin.
2,4-thiazolidinedione
The therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Gatifloxacin.
3-isobutyl-1-methyl-7H-xanthine
The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Gatifloxacin.
4-hydroxycoumarin
The therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Gatifloxacin.
6-O-benzylguanine
The metabolism of 6-O-benzylguanine can be decreased when combined with Gatifloxacin.
7-Deazaguanine
The metabolism of 7-Deazaguanine can be decreased when combined with Gatifloxacin.
7,9-Dimethylguanine
The metabolism of 7,9-Dimethylguanine can be decreased when combined with Gatifloxacin.
8-azaguanine
The metabolism of 8-azaguanine can be decreased when combined with Gatifloxacin.
8-chlorotheophylline
The metabolism of 8-chlorotheophylline can be decreased when combined with Gatifloxacin.
9-Deazaguanine
The metabolism of 9-Deazaguanine can be decreased when combined with Gatifloxacin.
9-Methylguanine
The metabolism of 9-Methylguanine can be decreased when combined with Gatifloxacin.
Abexinostat
The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Abexinostat.
Acarbose
The therapeutic efficacy of Acarbose can be increased when used in combination with Gatifloxacin.
Acebutolol
The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Acebutolol.
Aceclofenac
Aceclofenac may increase the neuroexcitatory activities of Gatifloxacin.
Acefylline
The metabolism of Acefylline can be decreased when combined with Gatifloxacin.
Acemetacin
Acemetacin may increase the neuroexcitatory activities of Gatifloxacin.
Acenocoumarol
The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Gatifloxacin.
Aceprometazine
The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Aceprometazine.
2 References
  1. 1 . Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, Dresser L, Low DE, Mamdani MM: Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med. 2006 Mar 30;354(13):1352-61. Epub 2006 Mar 1.PubMed: 16510739
  2. 2 . Gurwitz JH: Serious adverse drug effects--seeing the trees through the forest. N Engl J Med. 2006 Mar 30;354(13):1413-5. Epub 2006 Mar 1.PubMed: 16510740